Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tian, Dean
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Full data from P3 LUCENT 1 trial for severe ulcerative colitis Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis From LUCENT 1 trial for ulcerative colitis Mar 2021 - Mar 2021: From LUCENT 1 trial for ulcerative colitis Trial initiation in ulcerative colitis May 2018 - May 2018: Trial initiation in ulcerative colitis More	Completed	3	1281	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828, Placebo	Eli Lilly and Company	Ulcerative Colitis	01/21	05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis Safety and efficacy data from LUCENT-2 trial for ulcerative colitis Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis	Active, not recruiting	3	1177	Europe, Canada, Japan, US, RoW	Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC	Eli Lilly and Company	Ulcerative Colitis	11/21	12/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis	Recruiting	3	402	RoW	Vedolizumab IV, Placebo	Takeda	Moderately to Severely Active Ulcerative Colitis	05/28	07/28
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis	Terminated	2	70	RoW	Hemay007, Placebo	Tianjin Hemay Pharmaceutical Co., Ltd	Ulcerative Colitis	08/22	08/22